Comparing two doses of Aspirin for preventing strokes in patients with blunt cerebrovascular injury
Official title: Pilot, Non-masked, Randomized Clinical Trial for Evaluation of Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).
Run by Loma Linda University · NCT05868525 · Data updated 2026-11-12
This study tests whether a lower dose of Aspirin can prevent strokes just as well as a higher dose in adults with blunt cerebrovascular injury.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 98 (estimated) |
| Sponsor | Loma Linda University Academic / other |
| Locations | 1 site (Loma Linda, California) |
| Status | Recruiting |
| Started | August 23, 2023 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | January 30, 2026 |
| Trial ID | NCT05868525 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older diagnosed with blunt cerebrovascular injury confirmed by computed tomography angiography.
✕Probably not a fit
Patients under 18, pregnant women, or those with contraindications to Aspirin will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of two different doses of Aspirin (81 mg and 325 mg) in preventing strokes in patients diagnosed with blunt cerebrovascular injury. The study will assess whether the lower dose of Aspirin is as effective as the higher dose in preventing strokes and whether it results in fewer hemorrhagic complications. Patients will be monitored for stroke occurrence and any adverse effects related to the medication. The trial is designed for adults aged 18 and older who have been diagnosed with this specific type of injury.
Why it matters
Potential benefit: If successful, this study could provide insights into safer and equally effective dosing of Aspirin for stroke prevention in patients with blunt cerebrovascular injuries.
How similar studies have gone: While there have been studies on Aspirin for various conditions, this specific comparison of doses in blunt cerebrovascular injury is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 * All patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (CTA) upon admission Exclusion Criteria: * Age \<18 * Pregnant women * No enteral route access for Aspirin administration * Patients who are on Heparin drip or other full dose anticoagulation when BCVI diagnosed * Patients who are on other Anti-Platelets aside from Aspirin when BCVI diagnosed * Patients with BCVI grade 5 injury based on Biffl classification * Presence of any contraindication or history of allergy to Aspirin * Patient with the diagnosis of acute stroke at the time of BCVI diagnosis matching the injured vessel territory on imaging * Patients with acute spinal trauma that needs surgical intervention
Where it's running
-
Loma Linda University Medical Center
Loma Linda, California, United States Recruiting
Study contacts
- Study coordinator: Maryam B Tabrizi, M.D
- Email: MTabrizi@llu.edu
- Phone: (909) 558-4286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Erythropoietin Alfa to Improve Outcomes in Critically Ill Trauma Patients
This study is testing if a medication called epoetin alfa can help critically ill trauma patients recover better and reduce the risk of death or severe disability.
-
Developing a decision rule for safely assessing head injuries in patients on blood thinners
This study is testing a new guideline to help doctors safely determine if patients on blood thinners have a serious head injury after a bump to the head.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.